Medindia7h
Iv m Health Raises Alarm as FDA Deadline Threatens Obesity Treatment Access
In recognition of World Obesity Day,�Ivim Health is proud to advocate on behalf of patients on their health journeys by providing personalized and effective care, guided by medical professionals who ...
NewsNation on MSN14h
AbbVie enters into almost $2B contract with Gubra for obsesity drug
Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.
STAT19h
How the race for the next obesity drug is shaping up
While some drugs have fallen off, more have been added: AbbVie recently jumped into the obesity craze by licensing an ...
Zacks Investment Research on MSN23h
Here's How to Play AbbVie Stock as it Enters the Obesity Space
AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for ...